Login / Signup

Inhibition of 11β-Hydroxysteroid dehydrogenase-1 with AZD4017 in patients with nonalcoholic steatohepatitis or nonalcoholic fatty liver disease: A randomized, double-blind, placebo-controlled, phase II study.

Yogesh YadavKelly DunaganRachita KhotSudhakar K VenkateshJohn PortAlfonso GalderisiClaudio CobelliCraig WegnerAnanda BasuRickey CarterRita Basu
Published in: Diabetes, obesity & metabolism (2022)
C cortisol in the liver in all patients who received the drug. In patients with NASH and T2D, AZD4017 improved liver steatosis versus placebo.
Keyphrases
  • placebo controlled
  • phase ii study
  • double blind
  • phase iii
  • clinical trial
  • phase ii
  • study protocol
  • open label
  • insulin resistance
  • squamous cell carcinoma
  • radiation therapy
  • adverse drug
  • drug induced
  • liver fibrosis